Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Insulin Detemir Versus Neutral Protamine Hagedorn (NPH) Insulin in Pregnant Women With Type 1 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 1 diabetes treated with insulin for at least 12 months~* Planning to become pregnant and have a screening HbA1c (glycosylated haemoglobin) lesser than or equal to 9.0%, or~* Pregnant with an intrauterine singleton living foetus, 8-12 weeks pregnant when joining the trial and a HbA1c lesser than or equal to 8.0% when pregnancy is confirmed~Exclusion Criteria:~* Known or suspected hypersensitivity to the trial product(s) or related products~* Untreated hyperthyroidism or hypothyroidism~* Known or suspected abuse of alcohol or narcotics~* Cardiac problems~* Impaired kidney function~* History of severe hyperemesis gravidarum~* Treatment with in-vitro fertilisation or other medical infertility treatment~* Impaired liver function~* Uncontrolled hypertension~* Proliferative retinopathy or maculopathy requiring acute treatment~* Known to be HIV (human immunodeficiency virus) positive, Hepatitis B or Hepatitis C positive~* Any concomitant medication contraindicated in pregnancy

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Insulin detemir (Type: EXPERIMENTAL): Individually adjusted insulin detemir injected subcutaneously as basal insulin + individually adjusted insulin aspart injected subcutaneously as bolus insulin from randomisation (gestational week 8-12) and continued until 6 weeks after delivery. If a subject was not pregnant at randomisation, treatment was given up to a maximum of 52 weeks. For subjects who became pregnant, randomised treatment was continued until 6 weeks after delivery. Subjects who were not pregnant at 52 weeks after randomisation were withdrawn
- Neutral Protamine Hagedorn (NPH) insulin (Type: ACTIVE_COMPARATOR): Individually adjusted NPH insulin injected subcutaneously as basal insulin + individually adjusted insulin aspart injected subcutaneously as bolus insulin from randomisation (gestational week 8-12) and continued until 6 weeks after delivery. If a subject was not pregnant at randomisation, treatment was given up to a maximum of 52 weeks. For subjects who became pregnant, randomised treatment was continued until 6 weeks after delivery. Subjects who were not pregnant at 52 weeks after randomisation were withdrawn

Based on this trial design, predict the completion outcome and termination type (if applicable).